Latest NPH insulin Stories
Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators INDIANAPOLIS, Sept.
PRINCETON, N.J., Oct.
BRIDGEWATER, N.J., July 6 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the results of the long-term, 5-year study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in patients with type 2 diabetes, published on-line in Diabetologia (DOI 10.1007/s00125-009-1415-7) showed similar effects on retinopathy and overall safety in the two treatment groups.
- A1C and FBG Results for Patients 65 and Under Treated with Lantus and NPH were Similar - NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S.
WALTHAM, Mass., Aug.